中国抗体-B中期报告2023

目錄 21獨立審閱報告 53釋義 公司資料 15303305307 George William Hunter CAUTHERLEYDylan Carlo TINKER George William Hunter CAUTHERLEYDylan Carlo TINKER Dylan Carlo TINKER 183171712–1716 www.sinomab.com 3681 主席報告書 SM03 (Suciraslimab)RACD22RAIIISM03-RA-IIISuciraslimabIIICD22Suciraslimab(MTX)RASuciraslimabBLASuciraslimabBLA1012 SuciraslimabSuciraslimabMCIINDSuciraslimab BLASuciraslimabSuciraslimab SM17IL–25ISM17INDINDINDADINDISM17 SM17 6,0001,20036,000 主席報告書 管理層討論與分析 SM17First-in-ClassIL–25INDFDAI(FIH)77FIHSADMADADINDINDADIPF NCE SM03 (Suciraslimab)RASLESSMCINHLCD22SuciraslimabRAIIIBLASuciraslimabBLA1012 SN1011BTKSN1011SN10114INDSLEMSNMOSD SM06CD22SuciraslimabSuciraslimabSM06 管理層討論與分析 管理層討論與分析 RASuciraslimabSuciraslimabRAMCISSMCIIND SM03 (Suciraslimab) SM03 (Suciraslimab)(RA)(SLE)(SS)(MCI)(NHL)CD22Suciraslimab SM17 SM17(First-in-Class)IgG4–k(Alarmin)25(IL–25)IISM17IL–252(ILC2s)2T(Th2)(IL–17RB)Th2IL–4IL–5IL–13IL–25(AD)(IPF)SM17IL–252 SuciraslimabRAIIIIIISuciraslimab(MTX)(topline data)SuciraslimabRASuciraslimabRAIII530510III93BLASuciraslimabBLA1012Suciraslimab SM17IL–252SM17IgE1——2,4—(DNFB)SM17Th2Th2IL–25 管理層討論與分析 INDFDAI(FIH)I77(SAE)ISADMADPK IIPKSN10114INDSLEMSNMOSDSN1011SN1011 ADINDINDADINDISM17SM17ADIPFSM17 SM06 SM06CD22SM06SM03 (Suciraslimab)SM06SM06SM06SM06(SLE)(RA)SM06(CMC) SN1011 SN1011BTK(SLE)(MS)(NMOSD)SN1011BTK SM09 SM09CD20NHLCD20 管理層討論與分析 43,15875,0006,0001,20036,000 Everest Medicines II (HK) LimitedSN1011 4183SN1011 SM03 (Suciraslimab)RASLESSMCICD22SuciraslimabRASuciraslimabCD22SuciraslimabCD22CD22CD22BBRA 19,1631,200(CNC) 管理層討論與分析 SuciraslimabRAIIISuciraslimabRABLASuciraslimabBLA1012 SM03 (Suciraslimab)SM06SM06 SN1011 SM03 (Suciraslimab)RAIII530III93 SM09SM09 SM03 SuciraslimabPCTPCT • ••• SinoMab Suciraslimab40.9 18A.08 Suciraslimab 23337.7— 管理層討論與分析 SM03 (Suciraslimab) RASM03(Suciraslimab)SuciraslimabRABLAMCISuciraslimabSuciraslimabSuciraslimabMCIINDINDSSINDII 管理層討論與分析 SM17II77ADINDINDISM17ISM17AD SM06IND(PK) SN1011SN10114INDSLEMSNMOSDSN1011 SM09FDA SM06INDSuciraslimab D2M Biotherapeutics LimitedD2MD2M 管理層討論與分析 RARA280833SuciraslimabSuciraslimabSuciraslimab 43,15875,0006,00036,000 COVID-19 1,2051,6386.0%20205 管理層討論與分析 BTBIPF SM06SM09 B BBBBB IL–25IL–17RBSM17IL-25IgG4–k T a.CD22 —CD22SM03(Suciraslimab)SM06Bb.CD20—CD20SM09Bc.BTK —BTKSN1011B B— TT NatureCD22SM03 (Suciraslimab)MCICD22 CD22AβAβSM03(Suciraslimab)SM06 管理層討論與分析 7.20.7(i)1.4(ii)0.6 66.882.1(i)RAIII8.8(ii)3.9(iii)4.3 50.233.8(i)10.3(ii)2.5 20.0 286.5345.759.2(i)61.3(ii)62.8(iii)42.0(iv)19.1 管理層討論與分析 331.9268.83.30%0.30%0.40% 423.5 100% 0.130.15 管理層討論與分析 14.715.0 15 5% 獨立審閱報告 Ernst & Young27/F, One Taikoo Place,979 King’s Road,Quarry Bay, Hong Kong 2240343434 2410 34 中期簡明綜合權益變動表（續） 中期簡明綜合財務資料附註 1. 34 436 662(3)63406(2)407(2)407(3) 2. 179— 171717 — (a)12 2. (b)8 (c)1212 (i)(ii)12 (d)12— 中期簡明綜合財務資料附註 3. (a) 4. 4. (i)Everest Medicines II (HK) LimitedEverestBTK 5. 6. 中期簡明綜合財務資料附註 7. 25% 8. 9. 134,096,000143,790,0001,017,964,900988,144,900 10. 57,086,00029,326,000 11. (i)D2M7.29%7.68%A1 14. 15. 16. (a) 16. (c) 17. 17. 17. 18. 18. A 19. 其他資料 1,272.8 (1)(2)(3) 1.7828,680,00050,890,4001.771.78(i)1.78(ii)1.790.56%14,340,000 其他資料 0.049 25,156,02010,062,404 —E.36,174,400SkytechTechnology Limited36,174,400 10.07 其他資料 14A 10,062,40410,062,404 26,111,99626,111,996 14A.73(6)14A.95 10 50,312,0205%20,124,8082% 1,140,000 16,955,50016,955,50016,955,5001.64% 50,312,0205%10,062,4041%1.0025,156,02010,062,404 其他資料 50,312,0204.86%1% (i)(ii) a. XV352 (1) (2)1,034,920,400 (3)212,879,400Apricot Oversea Holdings LimitedWestBiolakeHoldings LimitedApricotBioScience Holdings, L.P.Zliverland Holdings Limited72,823,63646,711,64072,823,636 (4)Skytech Technology XV352 其他資料 XV23336 (1)(2)1,034,920,400(3)Skytech Technology(4)72,823,63646,711,640212,879,400Apricot Oversea Holdings LimitedWestBiolake HoldingsLimitedApricotBioScience Holdings L.P.Zliverland Holdings Limited(5)Apricot Oversea Holdings Limited9.0%1.47%Apricot Oversea Holding Limited(6)West Biolake Holdings LimitedWest Biolake Holdings Limited(7)West Biolake Holdings LimitedApricot Oversea Holdings LimitedApricotBioScience Holdings, L.P1.28%Zliverland Holdings Limited1.06%0.78%40%60%51%49%(8)158,882,115158,882,115(9)51,000,00051,000,000 336 其他資料 13.51B(1) 000566 13.51B C.2.1 C.2.1 (i)(ii)(iii)(iv)C.2.1 46 GeorgeWilliam Hunter CAUTHERLEYDylan Carlo TINKER 21 釋義 FDA Skytech TechnologySkytech Technology Limited 2 %